MRNA vs INCY — Key Metrics

Metric MRNA (MODERNA INC) INCY (INCYTE CORP)
Price196.79117.8
Market Cap79.63 Billion24.01 Billion
P/E (TTM)-27.856.36
P/B (Quarterly)15.0434.219
P/S (TTM)31.533.99
Net Profit Margin (TTM)-110.56.7
Gross Margin (TTM)28.092.7
ROE (TTM)-37.67.1
Revenue Growth YoY (TTM)n/an/a

Upfront Investment - S&P 500 Stock Comparison & AI Analysis

AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.

MODERNA INC
vs
 
INCYTE CORP
 
MODERNA INC
vs
 
INCYTE CORP
Performance Comparison
AI Model Recommendation
MRNA · MODERNA INC

Greatly Underperform

-94
UnderperformOutperform
INCY · INCYTE CORP

Greatly Outperform

84
UnderperformOutperform
Recommendation Summary

Stock MRNA is projected to greatly underperform the market, stock INCY is projected to greatly outperform the market. Upfront Recommendation: INCY.

Financial Metrics
Prices delayed ~15 min
MRNA Metrics INCY
$196.79 Price $117.80
— Market Capitalization —
31.53 Price to Sales 3.99
112.62 Price to Gross Profit 4.31
29.96 Price to R&D 6.99
10.84 Price to Current Assets 4.35

MRNA vs INCY at a glance

Moderna INC (MRNA) and Incyte Corp (INCY) are both Biotechnology companies in the Healthcare sector. MRNA is the larger, at $79.6 billion in market value against $24.0 billion for INCY, about 3.3 times the size.

On trailing-twelve-month figures, MRNA trades at 31.5 times trailing sales and INCY at 4.0; net profit margins are -110.5% and 6.7%.

The Upfront Investment model currently rates MRNA Greatly Underperform and INCY Greatly Outperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.